Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 9/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610756 | 1.00 | RET (0.35) | RETKDRACVR1TTKPIK3CD | |
| SCHEMBL16610980 | 0.91 | JAK2 (0.33) | RETKDRACVR1TTK | |
| SCHEMBL16610619 | 0.91 | JAK2 (0.33) | RETKDRACVR1TTK | |
| SCHEMBL16610641 | 0.91 | KDR (0.38) | RETKDR | |
| SCHEMBL16610592 | 0.91 | KDR (0.38) | RETKDR | |
| SCHEMBL16610547 | 0.91 | RET (0.37) | RETKDRACVR1PIK3CDPIK3R1 | |
| SCHEMBL16754754 | 0.90 | KDR (0.35) | KDRACVR1 | |
| SCHEMBL16754746 | 0.90 | KDR (0.35) | KDRACVR1 | |
| SCHEMBL18557037 | 0.90 | KDR (0.31) | KDR | |
| SCHEMBL16610653 | 0.89 | KDR (0.36) | KDRACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | claimed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | claimed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | claimed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | RET 628/4885KDR 2945/4885ACVR1 313/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | RET 10/4885KDR 301/4885ACVR1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.